MARKET

RVVTF

RVVTF

Revive Therapeutics Ltd
OTCMQB
0.022
NaN%
Opening 09:30 03/28 EDT
OPEN
--
PREV CLOSE
0.022
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.510
52 WEEK LOW
0.016
MARKET CAP
9.21M
P/E (TTM)
-2.2680
1D
5D
1M
3M
1Y
5Y
Revive Therapeutics Eyes FDA Approval for COVID Treatment
TipRanks · 1d ago
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. Has submitted a Type C meeting request package to the U.S. Food & Drug Administration for the evaluation of a proposed clinical study of Bucillamine. The Company expects to hear from the FDA on a firm date for the meeting. Revive is a specialty life sciences company.
Barchart · 1d ago
Weekly Report: what happened at RVVTF last week (0318-0322)?
Weekly Report · 3d ago
Revive Therapeutics Advances Bucillamine for Long COVID
TipRanks · 03/19 11:38
Weekly Report: what happened at RVVTF last week (0311-0315)?
Weekly Report · 03/18 10:42
Revive Therapeutics Researches Bucillamine Uses
TipRanks · 03/12 11:38
Weekly Report: what happened at RVVTF last week (0304-0308)?
Weekly Report · 03/11 10:40
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation. U.S. FDA issued breakthrough therapy designation for its LSD formulation for generalized anxiety disorder. After the announcement, Mind Medicine stock surged 55% to reach a new 52-week high. Other companies focused on psychedelic drugs also traded higher on Thursday.
Seeking Alpha · 03/07 16:29
More
About RVVTF
Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.

Webull offers Revive Therapeutics Ltd stock information, including OTCMQB: RVVTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVVTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVVTF stock methods without spending real money on the virtual paper trading platform.